title: Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers.
abstract: We addressed the clinicopathological significance of the oestrogen receptor (ER) beta protein, including an ERbeta variant, ERbetacx, in normal human breast and breast cancer. The reverse transcriptase-polymerase chain reaction (RT-PCR) showed that wild-type ERbeta (ERbetaw) mRNA expression was higher in normal than cancer tissues, and that ERbetacx mRNA was higher in cancer than in normal tissues. Immunohistochemistry of 22 normal breast tissues and 57 breast cancers was performed with three different ERbeta antibodies and one ERbetacx antibody. All normal breast samples showed staining with the three ERbeta antibodies, suggesting that ERbetaw might have a physiological role in oestrogen signalling in the normal breast. In breast cancer, expression of the ERbetaw protein correlated well with the expression of the ERalpha and progesterone receptor (PgR), as well as histological grade (HG), and tended to indicate a better prognosis than when ERbetaw was absent. Thirty-one (54%) breast cancer samples contained ERbetacx, whereas the corresponding tissue for normal breast samples stained positive in only two (9%).
authors.affiliation: Department of Surgery II, Nagoya City University Medical School, 1 Kawasumi, Mizuho-ku, 467-8601, Nagoya, Japan. yokomd-ngi@umin.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Omoto
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Inoue
authors.forename: S
authors.initials: S
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Toyama
authors.forename: H
authors.initials: H
authors.lastname: Yamashita
authors.forename: M
authors.initials: M
authors.lastname: Muramatsu
authors.forename: J-A
authors.initials: JA
authors.lastname: Gustafsson
authors.forename: H
authors.initials: H
authors.lastname: Iwase
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000379:methods; D047629:Estrogen Receptor beta; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D012313:RNA / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics* / Q000378:metabolism
chemical_list: D047629:Estrogen Receptor beta; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D012313:RNA